The year 2005 was another solid growth year for Novo Nordisk. In the markets, there is growing demand for the company's diabetes care products and biopharmaceuticals. In production, global sourcing and effiency gains are helping to curb costs and eco-efficiency measures are paying off in terms of significantly reduced consumption of water and energy. And across the organisation people are reinforcing the company's position as a values-based business. Click on the links on your left to read more about our 2005 financial results.
This page has been assessed by PricewaterhouseCoopers as part of its assessment of Novo Nordisk’s statement that it reports ‘in accordance’ with GRI. Please refer to Audit and assurance for a full description of the nature of assurance offered.
